Company
ImmuPharma PLC
LON:IMM
ImmuPharma PLC is a biopharmaceutical company that specializes in the usage and development of biopolymers, specifically peptides. The company is dedicated to developing an innovative portfolio of peptide-based therapeutic drugs with a focus on autoimmunity/inflammation and anti-infectives.
306 stories · page 1 of 4
ImmuPharma’s US partner confirms support for lupus treatment, wants to expand collaboration
"We have had extremely positive discussions with Avion over the last month"
ImmuPharma says it welcomes 'helpful' FDA recommendations ahead of phase III study
Lupuzor, also known as P140, is being taken through a final-stage study by ImmuPharma’s American partner Avion Pharmaceuticals
ImmuPharma says its US partner for Lupuzor has received a written response from the US FDA to its Type C meeting
The company said the FDA response was detailed and included significant guidance on next steps for the clinical programme
ImmuPharma raising £1.1mln to aid its R&D effort
The drug developer also unveiled a broker option to raise an additional £1.3mln
ImmuPharma hails quick response from FDA for Lupuzor planning meeting
The agreed date from the FDA for providing its written responses is 29 August 2022
ImmuPharma partner makes final preparations for phase III trial
Avion Pharmaceuticals has a licence and development agreement in the States for Lupuzor, also known as P140
ImmuPharma says it is in talks with partners for key assets as it hails progress made last year
It is in discussion with potential non-US licensees for its key asset Lupuzor, with its early-stage anti-infective also attracting attention
ImmuPharma says phase III trial preparations are underway
The clinical evaluation of Lupuzor will be overseen by the company’s US partner, Avion Pharmaceuticals
ImmuPharma drug clears a significant hurdle
Researchers have successfully completed a pharmacokinetic of the company's lead asset
ImmuPharma expects readout from pharmacokinetic by the end of the current quarter
The PK evaluation is part of the new, optimised international phase III trial of Lupuzor in patients with lupus, a condition where the immune system attacks the body’s own tissue and organs
ImmuPharma raises £3.55mln at a significant premium to Friday's share price
The cash injection will be used to fund research and development
ImmuPharma inks two-year collaboration agreement with Imperial College London
Chief operating officer, Dr Tim Franklin, said: "We are all extremely excited to be working with such a world-leading academic institute."
ImmuPharma says partnering discussions 'ongoing' for adaptations of lead asset
P140 is proving to be a platform technology rather than a single treatment
ImmuPharma says Lupozor inventor Sylviane Muller awarded Legion d’honneur
Lupuzor is being developed for the treatment of the autoimmune disease Lupus
ImmuPharma aims to save £1.1m per year in corporate rejig; lead asset prepares for further trials
The update follows a recent streamlining of the company’s board and management
Archive
Proactive headlines: ImmuPharma, Keywords Studios, Conroy Gold…
A look at some of today's main headlines from the Proactive newswire
ImmuPharma lupus drug to undergo pharmacokinetic study after FDA green light
The evaluation will take eight-to-12 weeks to complete
ImmuPharma bids farewell to CEO in boardroom re-shuffle
After 16 years with the company, Dimitri Dimitriou is handing over the reins to chairman Tim McCarthy
ImmuPharma appoints chief operating officer to the board
Dr Tim Franklin has been with the company for three years
ImmuPharma partner makes headway with US FDA
Avion Pharmaceuticals has been granted what’s called a Type C meeting with the Food & Drug Administration
ImmuPharma says international phase III trial remains on track to begin in the second half
The update followed guidance proffered by the US regulator after its meeting with Avion Pharmaceuticals in December, which is leading the development of ImmuPharma's lupus drug
ImmuPharma says US partner will meet FDA next month to gain regulator's insights on phase III lupus clinical trial
Avion Pharmaceuticals will also request the FDA consider conditional approval of the drug, whilst the final-stage trial is taking place
Archive
Proactive news headlines: ImmuPharma, Braveheart Investment, Plexus Holdings, 88 Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
ImmuPharma says US partner makes regulatory and operational progress ahead of phase III trial of lupus drug
The group said the US Food & Drug Administration has agreed to accept a submission made by Avion Pharmaceuticals supporting a request for a Type-A meeting
Streamlined ImmuPharma pushes ahead with drug research efforts
We take a closer look at ImmuPharma, the developer of a breakthrough drug for lupus
ImmuPharma reports reduced losses, eyes further Lupuzor progress
Looking ahead, the firm said it is awaiting final FDA guidance prior to commencing patient recruitment for a Phase III trial of Lupuzor, its proposed lupus treatment
ImmuPharma updates on US FDA Special Protocol Assessment submission for Lupuzor's Phase III trial
The group said its licensing partner, Avion has confirmed that as yet it has not received a response from the regulator and as such the file is still in the review queue, due to the current workload at the FDA
ImmuPharma raises £6.5mln to invest in pipeline of up-and-coming drugs
Chairman Tim McCarthy said the company was now in an “extremely robust position”
ImmuPharma partner looks to streamline phase III approval process for lupus drug
The special assessment protocol is a process that decides on the design and size of the study that will both meet the scientific and regulatory requirements and supports marketing approval for new drugs such as Lupuzor
ImmuPharma attracts first funding from US healthcare specialists
L1 Capital Global Opportunities Master Fund and Lind Global Macro Fund will receive unsecured convertible securities and associated options
Archive
Proactive news headlines: ImmuPharma, Tiziana Life Sciences, Echo Energy, Bango …
A glance at some of the day's highlights from the Proactive Investors newswire
ImmuPharma surges as US study shows potential for Lupuzor to reduce coronavirus symptoms
The drug development firm said the findings of the study suggested that coronavirus patients and lupus sufferers might share similar inflammatory symptoms, underpinned by similar mechanisms
ImmuPharma focused on the “optimum route forward
The update was provided alongside full-year 2019 results
ImmuPharma raises £1.5mln to expand R&D programmes
The funds have been raised through share subscriptions from chief scientific officer Robert Zimmer as well as significant shareholder Lanstead Capital
ImmuPharma’s Incanthera to list on NEX exchange imminently
Incanthera, which specialises in cancer treatments, is expecting to list on 28 February
ImmuPharma expects second phase III lupus trial to get underway as soon as possible this year
The UK company and its American partner concluded their first joint steering committee recently
ImmuPharma shares start trading on Euronext Growth Brussels
The dual listing on Euronext Growth Brussels aims to further increase the visibility of ImmuPharma's shares with European investors, the group said.
ImmuPharma says shares will be dual-listed on Euronext Growth Brussels with effect from 19 December
The group said the new listing does not affect the trading of its shares on AIM, nor is there any intention for it to raise additional funds from either AIM or Euronext
ImmuPharma’s Lupuzor could be US blockbuster, says Life Sciences Division
Investment bank Life Sciences Division upgraded its share price target to 100p from 76p on the back of the recent deal with US speciality drugs group Avion Pharmaceuticals
Small cap movers: ImmuPharma nearly trebles in value as US deal resurrects flagship Lupus drug
A look back at some of the more interesting stories from London's junior market this last week
Archive
Proactive news snapshot: Immupharma, Oracle Power, OPG Power Ventures, Faron Pharmaceuticals …
A glance at some of the day's highlights from the Proactive Investors newswire